Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Human immunodeficiency virus type 1 (HIV-1) infection is associated with impaired polymorphonuclear leukocyte (PMN) bactericidal activity.
• Dideoxynucleosides, including zidovudine (AZT), dideoxycytidine (ddC), and dideoxyinosine (ddI), are key agents in HIV-1 management.
• The impact of these antiviral agents on PMN function in HIV-1-infected individuals requires investigation.

Purpose of the Study:

• To evaluate the in vitro effects of AZT, ddC, and ddI on the functional activities of PMNs.
• To assess the influence of these dideoxynucleosides on PMNs from both healthy and HIV-1-infected individuals.

Main Methods:

• In vitro assessment of PMN viability, chemotaxis, phagocytosis, and superoxide production.
• Measurement of PMN bactericidal activity against Candida albicans and Staphylococcus aureus.
• Testing of dideoxynucleosides (AZT, ddC, ddI) across various concentrations.

Main Results:

• AZT, ddC, and ddI did not affect PMN viability, chemotaxis, phagocytosis, or superoxide production.
• ddC and ddI enhanced the killing of Candida albicans.
• ddI significantly enhanced the killing of Staphylococcus aureus and improved the defective bactericidal capacity of PMNs from HIV-1-infected patients.

Conclusions:

• Dideoxynucleosides, particularly ddI, can enhance certain PMN bactericidal functions.
• The findings suggest a potential therapeutic benefit of ddI in bolstering the immune response in HIV-1-infected individuals.
• Further research is warranted to explore the clinical implications of these observed enhancements in PMN function.